Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Lancet Oncol. 2011 Apr;12(4):361–368. doi: 10.1016/S1470-2045(11)70062-6

Figure 1. Distribution of time-to-event endpoints of Mantle Cell Lymphoma Patients treated with Temsirolimus and Rituximab (duration of response, time to progression, and overall survival).

Figure 1

A) Rituximab-sensitive patients (group 1), B) Rituximab-refractory patients (group 2).